What is Cincor Pharma?
Cincor Pharma is dedicated to pioneering novel pharmaceutical treatments for cardiovascular and metabolic diseases. The company's core strategy revolves around innovative mechanisms of action, particularly focusing on aldosterone modulation. By selectively reducing aldosterone levels, Cincor Pharma aims to offer significant clinical benefits to patients suffering from hypertension and related conditions who may not respond adequately to conventional therapies. Their lead therapeutic candidate is designed to address critical unmet medical needs in blood pressure management, targeting a specific physiological pathway that contributes to sustained hypertension and cardiovascular complications. The company's development strategy is broad, recognizing the diverse patient populations affected by these conditions and striving to improve long-term health trajectories and reduce cardiovascular risk.
How much funding has Cincor Pharma raised?
Cincor Pharma has raised a total of $386.6M across 3 funding rounds:
Series A
$50M
Series B
$143M
Stock Offering
$193.6M
Series A (2019): $50M with participation from Sofinnova Investments and 5AM Ventures
Series B (2021): $143M led by venBio Partners, Adage Capital Management, General Atlantic, and BVF Partners
Stock Issuance/Offering (2022): $193.6M, investors not publicly disclosed
Key Investors in Cincor Pharma
venBio Partners
venBio Partners is a life sciences investment firm that partners with industry leaders to develop innovative medicines and technologies, focusing on novel therapeutics for unmet medical needs. They provide strategic guidance on development plans to enhance patient care.
General Atlantic
General Atlantic is a global growthequity firm providing capital and strategic support to highgrowth companies in sectors including life sciences. They partner with founders and management teams to accelerate growth and transformational initiatives.
Adage Capital Management
Adage Capital Management is a money management firm primarily focused on S&P 500 assets, indicating a strategic approach to investment in established and growing companies.
What's next for Cincor Pharma?
The recent major strategic investment of $193.6M positions Cincor Pharma for accelerated growth and the advancement of its pipeline. This capital infusion is expected to fuel further research and development, potentially enabling the company to move its lead therapeutic candidates through critical clinical trial phases and towards commercialization. The company's focus on aldosterone modulation suggests a strategic intent to capture a significant share of the hypertension and cardiovascular market by offering a differentiated therapeutic approach. Future developments will likely involve strategic partnerships, regulatory milestones, and continued expansion of their scientific and clinical teams to support their ambitious goals in addressing complex cardiovascular and metabolic disorders.
See full Cincor Pharma company page
